Bristol Myers Squibb – Clinical Co-Development Collaboration

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401 (Focus on clinical development of TCR Bispecific program IMA401)

Post a comment